The Daily Chronicle
Business

Enveda Raises $311M to Move More Nature-Based AI Drugs Into Clinical Testing

The AI biotechnology company Enveda has secured $311 million in a funding round at a $2 billion valuation. It is currently testing treatments for skin conditions and for preserving weight loss after patients stop taking GLP-1s.

Sylvester Eyamah

By Sylvester Eyamah

Sep 24, 2026, 10:39 AM  ·  1 min read

Enveda Raises $311M to Move More Nature-Based AI Drugs Into Clinical Testing
Enveda Raises $311M to Move More Nature-Based AI Drugs Into Clinical Testing — Business
Enveda has raised $311 million in a financing round that values the AI-focused biotechnology company at $2 billion. The company is currently conducting trials on drug candidates intended to treat skin conditions and to help maintain weight loss after people discontinue GLP-1 medications.
Newsletter

Get the biggest stories in your inbox

A concise morning briefing, curated by Chronicle editors.